Daily Bio News Summary — 2026-07-10: FDA actions, clinical readouts, China-linked dealmaking, and endocrine M&A lead the harvest

Today’s harvest writes 26 article records from 6 free, live source URLs. The source mix is BioSpace (8), Fierce Pharma (6), BioPharma Dive (6), Fierce Biotech (4), FDA Newsroom (1), Reuters Biopharma (1). Category mix: Clinical Regulatory (11), Business & Strategy (10), Therapeutics Development (5).

Regulatory and FDA-facing activity

The regulatory thread is the clearest signal in this batch. FDA Newsroom anchors the day with a proposed rule to modernize drug manufacturing registration, while Fierce Pharma reports a third FDA rejection for Hengrui and Elevar’s PD-1 liver-cancer combination and a delayed FDA nod for Sanofi’s subcutaneous Sarclisa on-body injector. BioSpace also frames the first half of 2026 as approval-heavy in cancer and rare disease. Read together, the harvested frontmatter suggests a day where regulatory process, delivery formats, and cancer approvals matter more than broad market color.

Clinical development: setbacks and validation

Several items point in opposite directions for late-stage development. BioSpace reports AstraZeneca and Ionis’ Wainua setback in ATTR-CM, and BioSpace also reports Roche ending Huntington’s programs tied to Ionis. On the positive side, BioSpace covers GSK and Hansoh’s ADC late-stage win in China, while BioPharma Dive reports Kailera’s obesity pill succeeding in a late-stage China trial. The batch therefore reads less like a single therapeutic-area trend and more like a reminder that late-stage clinical risk remains highly program-specific.

Business development, M&A, and financing

Business-development coverage is broad. BioPharma Dive reports Vertex’s $10B Crinetics acquisition, Novartis’ ADC-developer deal worth up to $1.5B, and a broader note that cancer and immune drugmakers are dominating VC funding so far in 2026. Fierce Pharma adds BioNTech’s commercial groundwork for a PD-L1xVEGF program via a HER2 ADC. The frontmatter does not support a single unified thesis, but it does show continued capital concentration around oncology, endocrine disease, ADCs, and late-stage assets.

Tools, manufacturing, and infrastructure

Fierce Biotech reports ARPA-H awards of up to $160M for custom genetic medicines, while FDA Newsroom’s manufacturing-registration proposal and several company updates point toward infrastructure as a parallel story to drug readouts. These are not headline-grabbing acquisition items, but they shape how future therapies are registered, manufactured, or customized.

What this batch is NOT telling us

This is not a clean IPO window signal, not a broad AI-bio financing wave, and not a single-disease readout day. Paywalled Endpoints items and politically charged or policy-heavy items were excluded from the written set, so the synthesis intentionally reflects only the free, published article frontmatter that made it into the content collection.

Reading order

1. Start with the FDA manufacturing-registration proposal for the primary-source regulatory signal.
2. Read the Hengrui/Elevar FDA rejection and Sanofi Sarclisa injector items for immediate product-level regulatory impact.
3. Then read the AstraZeneca/Ionis Wainua and Roche/Huntington items for late-stage development risk.
4. Finish with Vertex/Crinetics, Novartis’ ADC-developer deal, and the VC-funding item for the business-development context.

How to read the underlying articles

Each item below corresponds to a markdown file in src/content/news/. The original article URL is stored in that file’s sourceUrl field.

All harvested items

1. FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time — Fierce Pharma, 2026-07-10. Fierce Pharma reports: FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time.
2. After FDA delay, Sanofi scores subcutaneous OBI nod for Sarclisa — Fierce Pharma, 2026-07-10. Fierce Pharma reports: After FDA delay, Sanofi scores subcutaneous OBI nod for Sarclisa.
3. A $10B deal, China trial scrutiny and highlights from ADA 2026 — Fierce Pharma, 2026-07-10. Fierce Pharma reports: A $10B deal, China trial scrutiny and highlights from ADA 2026.
4. AZ’s China deals, Kailera-Hengrui—Fierce Pharma Asia — Fierce Pharma, 2026-07-10. Fierce Pharma reports: AZ’s China deals, Kailera-Hengrui—Fierce Pharma Asia.
5. ARPA-H awards up to $160M for custom genetic medicines — Fierce Biotech, 2026-07-10. Fierce Biotech reports: ARPA-H awards up to $160M for custom genetic medicines.
6. Bausch + Lomb gives up on glaucoma eye drop hopeful after fail — Fierce Biotech, 2026-07-10. Fierce Biotech reports: Bausch + Lomb gives up on glaucoma eye drop hopeful after fail.
7. Idorsia locks in new CEO after shakeup—Chutes & Ladders — Fierce Biotech, 2026-07-10. Fierce Biotech reports: Idorsia locks in new CEO after shakeup—Chutes & Ladders.
8. FDA Proposes Rule to Modernize Drug Manufacturing Registration — FDA Newsroom, 2026-07-10. FDA Newsroom reports: FDA Proposes Rule to Modernize Drug Manufacturing Registration.
9. GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China — BioSpace, 2026-07-10. BioSpace reports: GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China.
10. AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space — BioSpace, 2026-07-10. BioSpace reports: AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space.
11. Roche scraps 2 Huntington’s studies, handing Ionis more bad news — BioSpace, 2026-07-10. BioSpace reports: Roche scraps 2 Huntington’s studies, handing Ionis more bad news.
12. Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up — BioSpace, 2026-07-10. BioSpace reports: Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up.
13. Amgen continues to defend Tavneos as global regulatory pressure mounts — BioSpace, 2026-07-10. BioSpace reports: Amgen continues to defend Tavneos as global regulatory pressure mounts.
14. Moderna wins EU contract for RSV vaccine supply — Reuters Biopharma, 2026-07-09. Reuters Biopharma reports: Moderna wins EU contract for RSV vaccine supply.
15. Sobi tops bleeding disorder patient groups’ reputation rankings — Fierce Pharma, 2026-07-09. Fierce Pharma reports: Sobi tops bleeding disorder patient groups’ reputation rankings.
16. BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC — Fierce Pharma, 2026-07-09. Fierce Pharma reports: BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC.
17. Illumina taps new commercial, legal chiefs — Fierce Biotech, 2026-07-09. Fierce Biotech reports: Illumina taps new commercial, legal chiefs.
18. Psychedelics surge again as Compass, Definium provide more clinical validation — BioSpace, 2026-07-09. BioSpace reports: Psychedelics surge again as Compass, Definium provide more clinical validation.
19. GSK ends brain drug alliance with Alector — BioPharma Dive, 2026-07-09. BioPharma Dive reports: GSK ends brain drug alliance with Alector.
20. Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal — BioPharma Dive, 2026-07-09. BioPharma Dive reports: Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal.
21. Vertex to acquire Crinetics in $10B foray into endocrine disease drugs — BioPharma Dive, 2026-07-09. BioPharma Dive reports: Vertex to acquire Crinetics in $10B foray into endocrine disease drugs.
22. Kailera says obesity pill succeeds in late-stage trial in China — BioPharma Dive, 2026-07-09. BioPharma Dive reports: Kailera says obesity pill succeeds in late-stage trial in China.
23. Cancer, immune drugmakers dominate VC funding so far in 2026 — BioPharma Dive, 2026-07-09. BioPharma Dive reports: Cancer, immune drugmakers dominate VC funding so far in 2026.
24. Novartis to acquire ADC developer in a deal worth up to $1.5B — BioPharma Dive, 2026-07-09. BioPharma Dive reports: Novartis to acquire ADC developer in a deal worth up to $1.5B.
25. Compass’ psilocybin depression drug works for the long haul — BioSpace, 2026-07-07. BioSpace reports: Compass’ psilocybin depression drug works for the long haul.
26. BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial — BioSpace, 2026-07-07. BioSpace reports: BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial.